Ladarixin With Sotorasib in Advanced NSCLC

This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT05815173
Phase
PHASE1
Sponsor
NYU Langone Health
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sotorasib
  • Ladarixin
Locations (sample)
  • Garden City, New York, United States|40.72677,-73.6343
  • Mineola, New York, United States|40.74927,-73.64068
  • New Hyde Park, New York, United States|40.7351,-73.68791
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Written informed consent, according to local guidelines, signed and dated by the participant prior to the performance of any study-specific procedu…
  • Participant must be ≥18 years of age at the time of signature of the informed consent form (ICF).
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →